FMP
Biogen Posts Q3 Earnings Beat and Raises 2024 Guidance
Oct 30, 2024 5:52 PM - Davit Kirakosyan
Image credit: FMP
Biogen (NASDAQ:BIIB) reported better-than-expected third-quarter results and raised its annual earnings guidance. The biotech firm posted Q3 earnings per share of $4.08, beating Wall Street expectations of $3.77, with revenue reaching $2.47 billion, slightly above the consensus of $2.43 billion.
The company’s multiple sclerosis segment generated $1.05 billion in revenue, close to estimates, while sales of Biogen's Alzheimer’s drug Leqembi rose to $67 million from about $40 million in the prior quarter.
Biogen raised its full-year 2024 EPS guidance to between $16.10 and $16.60, compared to the previous range of $15.75 to $16.25 and above the $16.19 consensus at the midpoint. The company maintained its outlook for a low-single-digit revenue decline compared to 2023, with core pharmaceutical revenue expected to stay roughly flat.
Other Blogs
Nov 22, 2024 5:08 AM - Parth Sanghvi
Fundamental Analysis: Principles, Types, and How to Use It
Fundamental analysis is one of the most essential tools for investors and analysts alike, helping them assess the intrinsic value of a stock, company, or even an entire market. It focuses on the financial health and economic position of a company, often using key data such as earnings, expenses, ass...
Dec 17, 2024 8:58 AM - Sanzhi Kobzhan
Examining Tesla’s Financial Health Using FinancialModelingPrep’s Ratios API
Tesla, one of the world’s most talked-about electric vehicle manufacturers, attracts a lot of attention from investors and market watchers. By examining a snapshot of Tesla’s financial ratios—such as those provided by FinancialModelingPrep’s Ratios API—we can get a clearer picture of the company’s f...
Dec 22, 2024 7:59 AM - Sanzhi Kobzhan
Two great Software Platform Stocks Similar to Palantir (PLTR)
When it comes to cutting-edge software and data analytics, Palantir Technologies (NYSE: PLTR) is often front and center. But for many investors, it’s important to consider alternative or complementary stocks in the same sector that may offer robust growth potential. As PLTR looks expensive (overvalu...
